Building Canada’s Pharmaceutical Strength at Home

February 12, 2026, Toronto - Canada’s pharmaceutical sector is navigating a period of meaningful change. Global supply chain disruptions, shifting trade dynamics, and renewed attention on health security have brought domestic manufacturing back into focus. At the same time, governments around the world are moving quickly to protect access to medicines and strengthen local production capacity.

In this environment, building pharmaceutical strength at home is not just a policy goal. It is a practical necessity for ensuring patient access, supporting economic resilience, and positioning Canada to compete globally.

Domestic Manufacturing as a Strategic Asset

Pharmaceutical manufacturing capacity is a cornerstone of a resilient healthcare system. Producing medicines in Canada reduces reliance on complex global supply chains and helps ensure a more stable supply of essential treatments for patients.

Domestic production also supports high-quality jobs and long-term investment across the life sciences sector. Manufacturing facilities, supply networks, and skilled workforces contribute to local economies while reinforcing Canada’s ability to respond to future health challenges.

Preparing for a Shifting Trade Environment

Global trade conditions are evolving rapidly, with increasing attention on tariffs, export controls, and reshoring strategies. For pharmaceutical manufacturers, trade uncertainty reinforces the importance of strong domestic foundations.

A robust manufacturing base enables Canada not only to meet domestic needs, but also to remain a reliable supplier to international markets. Export readiness depends on consistent production capacity, quality standards, and predictable policy frameworks, all of which are anchored in domestic strength.

Policy and Regulatory Conditions Matter

Long-term investment in pharmaceutical manufacturing depends on clarity and stability. Facilities are capital-intensive and designed to operate for decades, making predictable policy and regulatory environments essential.

Efficient regulatory performance also plays a critical role in patient access and affordability. Timely reviews and approvals support the availability of generic medicines, which help manage healthcare costs while maintaining high safety and quality standards.

When policy and regulation are aligned with industry realities, they support innovation, manufacturing growth, and improved access for patients.

Looking Ahead

Canada’s pharmaceutical sector has the expertise, infrastructure, and workforce needed to succeed in a competitive global landscape. Strengthening domestic manufacturing capacity, supporting innovation, and maintaining effective regulatory systems will be central to that success.

As trade dynamics continue to shift, investing in pharmaceutical strength at home will help ensure Canada remains resilient, competitive, and prepared to meet both domestic and global health needs.

---

The Canadian Pharmaceutical Manufacturers and Exporters Alliance (CPMEA) – Alliance fabricants et exportateurs pharmaceutiques du Canada (AFEPC) represents pharmaceutical companies that manufacture in Canada. We have come together in an Alliance to tell the story of drug production in Canada and to raise awareness of the unique issues facing our industry.

Click here to contact us, or email us directly at info@cpmea.ca.